Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024

• 2024

  Log in to bookmark this resource.

  Log in
• Brian Lefferts; Sara Bressler; James Keck; Christine Desnoyers; Ellen Hodges; Gerald January
PMID: 39541241DOI: https://dx.doi.org/10.15585/mmwr.mm7345a1

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This report looks at a study on the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) illness and hospitalization among Alaska Native children in the Yukon-Kuskokwim Delta region. Nirsevimab was found to be 89% effective against RSV hospitalizations for infants in their first season and 76-88% effective against medically attended illnesses for children in their first and second seasons. The study supports using nirsevimab to prevent severe RSV illness, especially among high-risk groups like American Indian and Alaska Native children, during their early RSV seasons.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Child; Hospitalization; Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Yukon Territory; American Indian or Alaska Native; Antibodies, Monoclonal, Humanized

Institutions: Centers for Disease Control and Prevention (CDC); Yukon-Kuskokwim Health Corporation

---

More like this

Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 2024 · Centers for Disease Control and Prevention (CDC), Maximus Federal Services, Inc., ICF Meeting Summary: State and Local Implementation Strategies for Increasing Access to Contraception During Zika Preparedness and Response — United States, September 2016 2017 · Centers for Disease Control and Prevention (CDC), Association of Schools & Programs of Public Health Notes from the Field: Rollout of Nirsevimab to Protect Infants and Young Children During the Respiratory Syncytial Virus Season — New York City, 2023–2024 2024 · New York City Department of Health and Mental Hygiene, Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---